June 25, 2022

Medical Trend

Medical News and Medical Resources

Keytruda for early-stage melanoma reaches more clinical endpoints

Keytruda for early-stage melanoma reaches more clinical endpoints



 

Delaying cancer recurrence: Keytruda for early-stage melanoma reaches more clinical endpoints


On March 07, Merck  announced another positive development for its blockbuster immunotherapy Keytruda.

The therapy met key secondary clinical endpoints in clinical trials as adjuvant therapy in resectable stage IIB and IIC melanoma.

 

Keytruda for early-stage melanoma reaches more clinical endpoints

 

Melanoma is one of the most serious types of skin cancer and is characterized by the uncontrolled growth of pigment-producing cells.

Early-stage melanoma can be treated with surgical resection, but melanoma has a high recurrence rate after resection: 32-46% for patients with stage IIB and IIC; 39-74% for patients with stage III %. The five-year survival rate of patients in these three stages is about 80% to 90%.

 

Keytruda is at the heart of Merck’s early-stage cancer treatment program, which states that treating cancer patients early can lead to better long-term survival. In a phase 3 clinical trial called KEYNOTE-716, researchers enrolled patients with stage IIB and IIC resectable melanoma.

The interim analysis showed that the treatment improved recurrence-free survival (RFS) relative to placebo.

The trial had previously met the primary clinical endpoint of RFS (HR=0.65 [95% CI, 0.46-0.92]; p=0.00658), and the FDA also expanded the indication for Keytruda based on these data.

Today’s results further demonstrate that the therapy, as adjuvant therapy, can statistically significantly improve distant metastasis-free survival (DMFS) with no new safety-signal concerns.

At future medical meetings, Merck plans to present more data.

 

 

 

References:

 https://www.merck.com/news/mercks-keytruda-pembrolizumab-demonstrated-significant-improvement-in-distant-metastasis-free-survival-dmfs-compared-to-placebo-as-adjuvant-therapy-for-patients-with-resected-stage/

Keytruda for early-stage melanoma reaches more clinical endpoints

(source:internet, reference only)


Disclaimer of medicaltrend.org